Shen Nian

Dr. Shen Nian

Department of Pathology, Xi’an Medical University, Xi’an, Shaanxi Province, China
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Eye and Vision
Verified
Journal Article
Open access
PDF file
SNShen Nian
Shen Nian
ALAmy C. Y. Lo
Amy C. Y. Lo
YMYajing Mi
Yajing Mi
KRKai Ren
Kai Ren
DYDi Yang
Di Yang
Diabetic retinopathy (DR), one of the common complications of diabetes, is the leading cause of visual loss in working-age individuals in many industrialized countries. It has been traditionally regarded as a purely microvascular disease in the retina. However, an increasing number of studies have shown that DR is a complex neurovascular disorder that affects not only vascular structure but also neural tissue of the retina. Deterioration of neural retina could precede microvascular abnormalities in the DR, leading to microvascular changes. Furthermore, disruption of interactions among neurons, vascular cells, glia and local immune cells, which collectively form the neurovascular unit, is considered to be associated with the progression of DR early on in the disease. Therefore, it makes sense to develop new therapeutic strategies to prevent or reverse retinal neurodegeneration, neuroinflammation and impaired cell-cell interactions of the neurovascular unit in early stage DR. Here, we present current perspectives on the pathophysiology of DR as a neurovascular disease, especially at the early stage. Potential novel treatments for preventing or reversing neurovascular injuries in DR are discussed as well.

18 May 2022 in Human Cell
Verified
Journal Article
Closed access
PDF file
SNShen Nian
Shen Nian
YMYajing Mi
Yajing Mi
KRKai Ren
Kai Ren
SWShanwei Wang
Shanwei Wang
MLMingkai Li
Mingkai Li
DYDi Yang
Di Yang

19 February 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
SNShen Nian
Shen Nian
YZYan Zeng
Yan Zeng
KHKatarina E. Heyden
Katarina E. Heyden
GCGaël Cagnone
Gaël Cagnone
HYHitomi Yagi
Hitomi Yagi
ZFZhongjie Fu
Zhongjie Fu
Background: Retinopathy of prematurity (ROP) is the major cause of blindness in children. It is a biphasic disease with retinal vessel growth cessation and loss (Phase I) followed by uncontrolled retinal vessel growth (Phase II). Folate is an essential nutrient for fetal development and growth. Premature infants have a high risk for folate deficiency. However, the contribution of folate to ROP risk remains unknown. Methods: In mouse oxygen-induced retinopathy (OIR), the nursing dams were fed with a folic acid-deficient or control diet after delivery until the end of hyperoxia. Alternatively, pups received direct injection of either folic acid or vehicle during Phase I hyperoxia. Genes involved in the folate cycle and angiogenic responses were examined using real-time PCR. Total retinal folate levels were measured with the Lactobacillus casei assay. Results: Maternal folic acid deficiency in early life exacerbated pathological retinal vessel growth, while supplementation with folic acid suppressed it. Genes involved in the folate cycle were downregulated in Phase I OIR retinas and were highly expressed in Müller glia. Folic acid reduced pro-angiogenic signaling in cultured rat retinal Müller glia in vitro. Conclusions: Appropriate supplementation of folic acid might be a new and safe treatment for ROP at an early stage.